22.418 articles found

Enhancement of neuroprotection of mulberry leaves (Morus alba L.) prepared by the anaerobic treatment against ischemic damage.

Kang TH, Oh HR, Jung SM, Ryu JH, Park MW, Park YK, Kim SY.

Biol Pharm Bull · 2006-02-01

DOI: 10.1248/bpb.29.270PMID: 16462030

Green tea catechins as brain-permeable, natural iron chelators-antioxidants for the treatment of neurodegenerative disorders.

Mandel S, Amit T, Reznichenko L, Weinreb O, Youdim MB.

Mol Nutr Food Res · 2006-02-01

DOI: 10.1002/mnfr.200500156PMID: 16470637

Crossroads in GDNF therapy for Parkinson's disease.

Sherer TB, Fiske BK, Svendsen CN, Lang AE, Langston JW.

Mov Disord · 2006-02-01

DOI: 10.1002/mds.20861PMID: 16470786

Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990.

Van Gerpen JA, Kumar N, Bower JH, Weigand S, Ahlskog JE.

Arch Neurol · 2006-02-01

DOI: 10.1001/archneur.63.2.205PMID: 16476808

A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations.

Blindauer K, Shoulson I, Oakes D, Kieburtz K, Schwid S, Fahn S, Stern M, Goetz C, Nutt J, Goren S, Sayag N, Scolnik M, Levy R, Eyal E, Salzman P, Pagano M, Parkinson Study Group.

Arch Neurol · 2006-02-01

DOI: 10.1001/archneur.63.2.210PMID: 16476809

Association between pathologic gambling and parkinsonian therapy as detected in the Food and Drug Administration Adverse Event database.

Szarfman A, Doraiswamy PM, Tonning JM, Levine JG.

Arch Neurol · 2006-02-01

DOI: 10.1001/archneur.63.2.299-bPMID: 16476828

Radical radiation therapy in a patient with head and neck cancer and severe Parkinson's disease.

Mazdai G, Stewart DP, Hounsell AR.

Clin Oncol (R Coll Radiol) · 2006-02-01

DOI: 10.1016/j.clon.2005.09.009PMID: 16477925

Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study.

Jabre MG, Bejjani BP.

Neurology · 2006-02-01

DOI: 10.1212/01.wnl.0000216108.57529.b1PMID: 16505339

Dopamine receptor pharmacology: interactions with serotonin receptors and significance for the aetiology and treatment of schizophrenia.

Werkman TR, Glennon JC, Wadman WJ, McCreary AC.

CNS Neurol Disord Drug Targets · 2006-02-01

DOI: 10.2174/187152706784111614PMID: 16613551

The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders.

Sokoloff P, Diaz J, Le Foll B, Guillin O, Leriche L, Bezard E, Gross C.

CNS Neurol Disord Drug Targets · 2006-02-01

DOI: 10.2174/187152706784111551PMID: 16613552

Role of lifestyle factors on plasma homocysteine levels in Parkison's disease patients treated with levodopa.

Siniscalchi A, Gallelli L, Mercuri NB, Ibbadu GF, De Sarro G.

Nutr Neurosci · 2006-02-01

DOI: 10.1080/10284150600583446PMID: 16910165

IMPROVING AND PROTECTING CELL THERAPY FOR NEUROLOGICAL DISORDERS INCLUDING PARKINSON'S DISEASE

ABELIOVICH Asa, MARTINAT Cecile.

· 2006-01-31